Authors:
DI Jodrell, IE Smith
Journal name: 
Cancer Chemother Pharmacol
Citation info: 
26(1):62-64
Abstract: 
A total of 13 patients with metastatic carcinoid tumour, paraganglioma, or unclassified "apudoma" were treated with single-agent carboplatin at a dose of 400 mg/m2 given by intravenous infusion every 4 weeks, on the basis that this new agent shows high activity against small-cell lung cancer that also has "apudoma" characteristics. No objective tumour responses were seen. Overall, 2 patients achieved minor regression, 4/9 (44%) showed a reduction of greater than 50% in urinary 5-HIAA excretion and 8/13 (62%) reported symptomatic improvement. Treatment was well tolerated, with neutropenia and thrombocytopenia being the main toxicities. Carboplatin, like other cytotoxic agents, does not appear to have major activity against these tumours, although further studies in patients with metastatic paraganglioma are warranted.
DOI: 
http://doi.org/10.1007/bf02940296
Research group: 
Jodrell Group
E-pub date: 
01 Aug 1990
Users with this publication listed: 
Duncan Jodrell